| |
| |
| Exchange: |
American Stock Exchange |
| Security
Type: |
Common |
| Shares
Out: |
26,020,000 |
| Market
Cap: |
190.21(M) |
| Last
Volume: |
6,675 |
Avg
Vol: |
6,657 |
| 52
Week Range: |
$6.48 - $11.61 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Health Services |
| Level
III Sector: |
Home Health Care |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Fennec Pharmaceuticals is a biopharmaceutical company focused on the development of PEDMARK™ (sodium thiosulfate anhydrous injection) for the prevention of platinum-induced ototoxicity in pediatric cancer patients. Co. has licensed from Oregon Health & Science University intellectual property rights for the use of PEDMARK™ as a chemoprotectant and is developing PEDMARK™ as a protectant against the hearing loss caused by platinum-based anti-cancer agents in children.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
41,667 |
41,667 |
41,667 |
41,667 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
2 |
2 |
2 |
2 |
| Total Buy Transactions |
2 |
2 |
2 |
2 |
| Total Shares Sold |
384,683 |
419,998 |
481,476 |
532,549 |
| Total Sell Value |
$3,266,840 |
$3,642,187 |
$4,152,217 |
$4,642,390 |
| Total People Sold |
4 |
4 |
4 |
4 |
| Total Sell Transactions |
18 |
23 |
31 |
38 |
| End Date |
2024-02-18 |
2023-11-17 |
2023-05-19 |
2022-05-19 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Rallis Chris A |
Director |
– • – |
2023-12-26 |
4 |
S |
$10.90 |
$15,151 |
D/D |
(1,390) |
44,788 |
|
19% |
|
| Rallis Chris A |
|
– • – |
2023-11-20 |
4 |
AS |
$8.25 |
$2,219 |
D/D |
(269) |
43,034 |
|
29% |
|
| Islam Khalid |
|
– • – |
2023-11-16 |
4 |
OE |
$1.13 |
$441,400 |
D/D |
213,825 |
213,825 |
|
- |
|
| Raykov Rosty |
CHIEF EXECUTIVE OFFICER |
• • – |
2023-11-08 |
4 |
S |
$7.69 |
$194,267 |
D/D |
(25,044) |
282,587 |
|
-45% |
|
| Rallis Chris A |
|
– • – |
2023-08-18 |
4 |
S |
$7.85 |
$5,283 |
D/D |
(673) |
43,303 |
|
-47% |
|
| Rallis Chris A |
|
– • – |
2023-07-24 |
4 |
S |
$8.17 |
$55,523 |
D/D |
(6,796) |
43,976 |
|
-6% |
|
| Rallis Chris A |
|
– • – |
2023-07-24 |
4 |
OE |
$0.72 |
$12,000 |
D/D |
16,666 |
50,772 |
|
- |
|
| Rallis Chris A |
|
– • – |
2023-07-06 |
4 |
OE |
$0.96 |
$5,069 |
D/D |
5,280 |
34,106 |
|
- |
|
| Rallis Chris A |
|
– • – |
2023-07-06 |
4 |
S |
$8.47 |
$18,693 |
D/D |
(2,207) |
28,826 |
|
12% |
|
| Andrade Robert |
CHIEF FINANCIAL OFFICER |
• – – |
2023-06-30 |
4 |
OE |
$2.45 |
$61,250 |
D/D |
25,000 |
149,721 |
|
- |
|
| Andrade Robert |
CHIEF FINANCIAL OFFICER |
• – – |
2023-06-30 |
4 |
AS |
$8.82 |
$66,150 |
D/D |
(7,500) |
124,721 |
|
-8% |
|
| Andrade Robert |
CHIEF FINANCIAL OFFICER |
• – – |
2023-06-29 |
4 |
AS |
$8.97 |
$67,275 |
D/D |
(7,500) |
132,221 |
|
-10% |
|
| Andrade Robert |
CHIEF FINANCIAL OFFICER |
• – – |
2023-06-28 |
4 |
AS |
$8.99 |
$89,900 |
D/D |
(10,000) |
139,721 |
|
-26% |
|
| Rallis Chris A |
|
– • – |
2023-05-19 |
4 |
AS |
$7.36 |
$12,939 |
D/D |
(1,758) |
31,033 |
|
-4% |
|
| Rallis Chris A |
|
– • – |
2023-04-17 |
4 |
D |
$8.34 |
$8,223 |
D/D |
(986) |
32,791 |
|
- |
|
| Rallis Chris A |
|
– • – |
2023-04-17 |
4 |
OE |
$2.94 |
$4,998 |
D/D |
1,700 |
33,777 |
|
- |
|
| Rallis Chris A |
|
– • – |
2023-03-03 |
4 |
D |
$9.09 |
$19,789 |
D/D |
(2,177) |
32,077 |
|
- |
|
| Rallis Chris A |
|
– • – |
2023-03-03 |
4 |
OE |
$2.40 |
$9,998 |
D/D |
4,166 |
34,184 |
|
- |
|
| Raykov Rosty |
CHIEF EXECUTIVE OFFICER |
• • – |
2022-12-30 |
4 |
S |
$9.61 |
$96,207 |
D/D |
(10,000) |
217,838 |
|
18% |
|
| Andrade Robert |
CHIEF FINANCIAL OFFICER |
• – – |
2022-12-30 |
4 |
AS |
$9.61 |
$52,867 |
D/D |
(5,500) |
149,721 |
|
-18% |
|
| Raykov Rosty |
CHIEF EXECUTIVE OFFICER |
• • – |
2022-12-29 |
4 |
S |
$9.65 |
$48,250 |
D/D |
(5,000) |
227,838 |
|
18% |
|
| Andrade Robert |
CHIEF FINANCIAL OFFICER |
• – – |
2022-12-29 |
4 |
AS |
$9.57 |
$52,661 |
D/D |
(5,500) |
155,221 |
|
-18% |
|
| Raykov Rosty |
CHIEF EXECUTIVE OFFICER |
• • – |
2022-12-28 |
4 |
S |
$9.59 |
$131,767 |
D/D |
(13,740) |
232,838 |
|
18% |
|
| Andrade Robert |
CHIEF FINANCIAL OFFICER |
• – – |
2022-12-28 |
4 |
AS |
$9.61 |
$105,760 |
D/D |
(11,000) |
160,721 |
|
-18% |
|
| Rallis Chris A |
|
– • – |
2022-11-17 |
4 |
AS |
$7.99 |
$2,661 |
D/D |
(333) |
30,018 |
|
2% |
|
56 Records found
|
|
Page 2 of 3 |
|
|
0.27 (3.84%) 
